Lista de obras - Richard Adams - Dominio Público Uruguay

A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network.

artículo científico publicado en 2007

A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? ⬇️

artículo científico publicado en 2014

A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network

scientific article published on 22 November 2006

A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protoc ⬇️

artículo científico publicado en 2017

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial ⬇️

artículo científico publicado el 5 de junio de 2011

Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation.

artículo científico publicado en 2014

Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial

scientific article published on 30 August 2019

Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Anal Cancer

artículo científico publicado en 2017

Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Multidisciplinary Management

artículo científico publicado en 2017

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

artículo científico publicado en 2015

CRIB--the use of cardiac rehabilitation services to aid the recovery of patients with bowel cancer: a pilot randomised controlled trial (RCT) with embedded feasibility study.

artículo científico publicado en 2014

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.

artículo científico publicado en 2008

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option

artículo científico publicado en 2010

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database ⬇️

artículo científico publicado en 2017

Clinical development of new drug-radiotherapy combinations ⬇️

artículo científico publicado en 2016

Clinical endpoints in trials of chemoradiation for patients with anal cancer.

artículo científico publicado en 2017

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD da ⬇️

artículo científico publicado en 2018

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab

artículo científico publicado en 2017

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group

artículo científico publicado en 2018

Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. ⬇️

artículo científico publicado en 2018

Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study

artículo científico publicado en 2016

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.

artículo científico publicado en 2017

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis

artículo científico publicado en 2011

Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.

artículo científico publicado en 2017

End points in anal cancer: hopes for a common language.

artículo científico publicado en 2014

Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer

artículo científico publicado en 2015

Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer.

artículo científico publicado en 2013

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 tri

artículo científico

HER2-HER3 heterodimer quantification by FRET-FLIM and patient subclass analysis of the COIN colorectal trial

scientific article published on 18 December 2019

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials

artículo científico publicado en 2017

Image-guided radiotherapy for rectal cancer: a systematic review

artículo científico publicado en 2011

Imaging for target volume delineation in rectal cancer radiotherapy--a systematic review

artículo científico publicado en 2011

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system d

artículo científico publicado en 2015

Initial Results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015. ⬇️

artículo científico publicado en 2016

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial

artículo científico publicado en 2014

Intermittent therapy in the palliative treatment of metastatic colorectal cancer.

artículo científico publicado en 2009

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial ⬇️

artículo científico publicado el 5 de junio de 2011

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials ⬇️

artículo científico publicado en 2016

Is referral of postsurgical colorectal cancer survivors to cardiac rehabilitation feasible and acceptable? A pragmatic pilot randomised controlled trial with embedded qualitative study.

artículo científico publicado en 2016

Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer.

artículo científico publicado en 2008

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.

artículo científico publicado en 2012

Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell Carcinoma

scientific article published on 17 October 2019

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy

scientific article published on 13 August 2018

Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer

artículo científico publicado en 2016

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial ⬇️

artículo científico publicado en 2015

Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.

artículo científico publicado en 2007

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database ⬇️

artículo científico publicado en 2016

Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I).

artículo científico publicado en 2012

Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies ⬇️

artículo científico publicado en 2018

Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?

artículo científico publicado en 2018

Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma

artículo científico publicado en 2009

Surveillance of Anal Canal Cancers.

artículo científico publicado en 2017

Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?

artículo científico publicado en 2018

Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary data

artículo científico publicado en 2017

Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations

artículo científico publicado en 2016

The Development of an Umbrella Trial (PLATO) to Address Radiation Therapy Dose Questions in the Locoregional Management of Squamous Cell Carcinoma of the Anus

article published in 2016

The Three-item ALERT-B Questionnaire Provides a Validated Screening Tool to Detect Chronic Gastrointestinal Symptoms after Pelvic Radiotherapy in Cancer Survivors.

artículo científico publicado en 2016

The physician-patient relationship in the age of precision medicine

artículo científico publicado en 2018

Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort ⬇️

article

What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. ⬇️

artículo científico publicado en 2014

Where now for anti-EGF receptor therapies in colorectal cancer?

artículo científico publicado en 2011

Wide Variation in the Use of Radiotherapy in the Management of Surgically Treated Rectal Cancer Across the English National Health Service ⬇️

artículo científico publicado en 2016

“Mind the Gap”—The Impact of Variations in the Duration of the Treatment Gap and Overall Treatment Time in the First UK Anal Cancer Trial (ACT I)

article

Lista de obras de Richard Adams

A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network.

A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? ⬇️

A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network

A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protoc ⬇️

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial ⬇️

Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation.

Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial

Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Anal Cancer

Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Multidisciplinary Management

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

CRIB--the use of cardiac rehabilitation services to aid the recovery of patients with bowel cancer: a pilot randomised controlled trial (RCT) with embedded feasibility study.

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database ⬇️

Clinical development of new drug-radiotherapy combinations ⬇️

Clinical endpoints in trials of chemoradiation for patients with anal cancer.

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD da ⬇️

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group

Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. ⬇️

Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis

Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.

End points in anal cancer: hopes for a common language.

Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer

Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 tri

HER2-HER3 heterodimer quantification by FRET-FLIM and patient subclass analysis of the COIN colorectal trial

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials

Image-guided radiotherapy for rectal cancer: a systematic review

Imaging for target volume delineation in rectal cancer radiotherapy--a systematic review

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system d

Initial Results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015. ⬇️

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial

Intermittent therapy in the palliative treatment of metastatic colorectal cancer.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial ⬇️

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials ⬇️

Is referral of postsurgical colorectal cancer survivors to cardiac rehabilitation feasible and acceptable? A pragmatic pilot randomised controlled trial with embedded qualitative study.

Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer.

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.

Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell Carcinoma

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy

Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial ⬇️

Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database ⬇️

Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I).

Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies ⬇️

Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?

Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma

Surveillance of Anal Canal Cancers.

Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?

Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary data

Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations

The Development of an Umbrella Trial (PLATO) to Address Radiation Therapy Dose Questions in the Locoregional Management of Squamous Cell Carcinoma of the Anus

The Three-item ALERT-B Questionnaire Provides a Validated Screening Tool to Detect Chronic Gastrointestinal Symptoms after Pelvic Radiotherapy in Cancer Survivors.

The physician-patient relationship in the age of precision medicine

Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort ⬇️

What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. ⬇️

Where now for anti-EGF receptor therapies in colorectal cancer?

Wide Variation in the Use of Radiotherapy in the Management of Surgically Treated Rectal Cancer Across the English National Health Service ⬇️

“Mind the Gap”—The Impact of Variations in the Duration of the Treatment Gap and Overall Treatment Time in the First UK Anal Cancer Trial (ACT I)